Search Results - "Thomas, Cameron D"

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing by Lima, John J., Thomas, Cameron D., Barbarino, Julia, Desta, Zeruesenay, Van Driest, Sara L., El Rouby, Nihal, Johnson, Julie A., Cavallari, Larisa H., Shakhnovich, Valentina, Thacker, David L., Scott, Stuart A., Schwab, Matthias, Uppugunduri, Chakradhara Rao S., Formea, Christine M., Franciosi, James P., Sangkuhl, Katrin, Gaedigk, Andrea, Klein, Teri E., Gammal, Roseann S., Furuta, Takahisa

“…Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux…”
Get full text

Pharmacogenetics of P2Y12 receptor inhibitors by Thomas, Cameron D., Williams, Alexis K., Lee, Craig R., Cavallari, Larisa H.

“…Oral P2Y12 inhibitors are commonly prescribed for cardiovascular disease and include clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its…”
Get full text

Impact of the ABCD‐GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi‐Site, Real‐World Investigation by Thomas, Cameron D., Franchi, Francesco, Keeley, Ellen C., Rossi, Joseph S., Winget, Marshall, David Anderson, R., Dempsey, Alyssa L., Gong, Yan, Gower, Megan N., Kerensky, Richard A., Kulick, Natasha, Malave, Jean G., McDonough, Caitrin W., Mulrenin, Ian R., Starostik, Petr, Beitelshees, Amber L., Johnson, Julie A., Stouffer, George A., Winterstein, Almut G., Angiolillo, Dominick J., Lee, Craig R., Cavallari, Larisa H.

“…The Age, Body mass index, Chronic kidney disease, Diabetes mellitus, and CYP2C19 GENEtic variants (ABCD‐GENE) score was developed to identify patients at risk…”
Get full text

CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings by Beitelshees, Amber L, Thomas, Cameron D, Empey, Philip E, Stouffer, George A, Angiolillo, Dominick J, Franchi, Francesco, Tuteja, Sony, Limdi, Nita A, Lee, James C, Duarte, Julio D, Kreutz, Rolf P, Skaar, Todd C, Coons, James C, Giri, Jay, McDonough, Caitrin W, Rowland, Rachel, Stevenson, James M, Thai, Thuy, Vesely, Mark R, Wellen, Jacob T, Johnson, Julie A, Winterstein, Almut G, Cavallari, Larisa H, Lee, Craig R

“…Background Studies have demonstrated increased risk of major atherothrombotic events in loss-of-function (LOF) variant carriers versus non-carriers treated…”
Get full text

CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention by Tunehag, Kayla R, Thomas, Cameron D, Franchi, Francesco, Rossi, Joseph S, Keeley, Ellen C, Anderson, R David, Beitelshees, Amber L, Duarte, Julio D, Gong, Yan, Kerensky, Richard A, McDonough, Caitrin W, Nguyen, Anh B, Ortega-Paz, Luis, Venkatesh, Sanjay, Wang, Yehua, Johnson, Julie A, Winterstein, Almut G, Stouffer, George A, Angiolillo, Dominick J, Cavallari, Larisa H, Lee, Craig R

“…Cytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary…”
Get full text

Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies by Cavallari, Larisa H., Lee, Craig R., Franchi, Francesco, Keeley, Ellen C., Rossi, Joseph S., Thomas, Cameron D., Gong, Yan, McDonough, Caitrin W., Starostik, Petr, Al Saeed, Maryam J., Been, Latonya, Kulick, Natasha, Malave, Jean, Mulrenin, Ian R., Nguyen, Anh B., Terrell, Joshua N., Tillotson, Grace, Beitelshees, Amber L., Winterstein, Almut G., Stouffer, George A., Angiolillo, Dominick J.

“…Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary…”
Get full text

Pharmacogenetic factors affecting β-blocker metabolism and response by Thomas, Cameron D, Johnson, Julie A

“…β-blockers are among the most widely prescribed of all drugs, used for treatment of a large number of cardiovascular diseases. Herein we evaluate literature…”
Get more information

How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial by Cicali, Emily J., Elchynski, Amanda L., Cook, Kelsey J., Houder, John T., Thomas, Cameron D., Smith, D. Max, Elsey, Amanda, Johnson, Julie A., Cavallari, Larisa H., Wiisanen, Kristin

“…CYP2D6 genotype is increasingly being integrated into practice to guide prescribing of certain medications. The CYP2D6 drug metabolizing enzyme is susceptible…”
Get full text

Pharmacogenetics of P2Y 12 receptor inhibitors by Thomas, Cameron D, Williams, Alexis K, Lee, Craig R, Cavallari, Larisa H

“…Oral P2Y inhibitors are commonly prescribed for cardiovascular disease and include clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its…”
Get full text

Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction by AlSaeed, Maryam Jamal, Thomas, Cameron D., Franchi, Francesco, Keeley, Ellen C., Duarte, Julio D., Gong, Yan, Rossi, Joseph S., Beitelshees, Amber L., Stouffer, George A., Lee, Craig R., Angiolillo, Dominick J., Cavallari, Larisa H.

“…The ABCD‐GENE score was developed to predict poor response to clopidogrel and includes Age, Body mass index, Chronic kidney disease (CKD; estimated glomerular…”
Get full text

Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center by Cicali, Emily J, Elchynski, Amanda, Thomas, Cameron D, Alam, Benish, Dalton, Rachel, Davis, Rick, Eken, Eda, Estores, David, Nguyen, Khoa, Cavallari, Larisa H, Wiisanen, Kristin

“…Abstract Purpose To describe the implementation of CYP2C19 testing into clinical practice at University of Florida (UF) Health Gainesville hospital to guide…”
Get full text

Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score by Thomas, Cameron D., Franchi, Francesco, Rossi, Joseph S., Keeley, Ellen C., Anderson, R. David, Beitelshees, Amber L., Duarte, Julio D., Ortega-Paz, Luis, Gong, Yan, Kerensky, Richard A., Kulick, Natasha, McDonough, Caitrin W., Nguyen, Anh B., Wang, Yehua, Winget, Marshall, Yang, William E., Johnson, Julie A., Winterstein, Almut G., Stouffer, George A., Angiolillo, Dominick J., Lee, Craig R., Cavallari, Larisa H.

“…An ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score ≥10 predicts reduced clopidogrel effectiveness, but…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy by Duarte, Julio D., Thomas, Cameron D., Lee, Craig R., Huddart, Rachel, Agundez, Jose A. G., Baye, Jordan F., Gaedigk, Andrea, Klein, Teri E., Lanfear, David E., Monte, Andrew A., Nagy, Mohamed, Schwab, Matthias, Stein, C. Michael, Uppugunduri, Chakradhara Rao S., Schaik, Ron H. N., Donnelly, Roseann S., Caudle, Kelly E., Luzum, Jasmine A.

“…Beta‐blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension…”
Get full text

Impact of the CYP2C1917 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention by Lee, Craig R., Thomas, Cameron D., Beitelshees, Amber L., Tuteja, Sony, Empey, Philip E., Lee, James C., Limdi, Nita A., Duarte, Julio D., Skaar, Todd C., Chen, Yiqing, Cook, Kelsey J., Coons, James C., Dillon, Chrisly, Franchi, Francesco, Giri, Jay, Gong, Yan, Kreutz, Rolf P., McDonough, Caitrin W., Stevenson, James M., Weck, Karen E., Angiolillo, Dominick J., Johnson, Julie A., Stouffer, George A., Cavallari, Larisa H.

“…Genotyping for CYP2C19 no function alleles to guide antiplatelet therapy after percutaneous coronary intervention (PCI) improves clinical outcomes. Although…”
Get full text

A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management by Thomas, Cameron D., Parvataneni, Hari K., Gray, Chancellor F., Deen, Justin T., Prieto, Hernan A., Pulido, Luis F., Elsey, Amanda R., Elwood, Erica N., Starostik, Petr, Gong, Yan, Fillingim, Roger B., Johnson, Julie A., Cavallari, Larisa H.

“…Cytochrome P450 2D6 (CYP2D6) genotype–guided opioid prescribing is limited. The purpose of this type 2 hybrid implementation-effectiveness trial was to…”
Get full text

Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y 12 Inhibitor Prescribing After Percutaneous Coronary Intervention by Cavallari, Larisa H, Limdi, Nita A, Beitelshees, Amber L, Lee, James C, Duarte, Julio D, Franchi, Francesco, Tuteja, Sony, Giri, Jay, Empey, Philip E, Kreutz, Rolf P, Skaar, Todd C, Allen, John M, Coons, James C, Gong, Yan, McDonough, Caitrin W, Stevenson, James M, Thomas, Cameron D, Johnson, Julie A, Stouffer, George A, Angiolillo, Dominick J, Lee, Craig R

“…Black patients suffer worse outcomes after percutaneous coronary intervention (PCI) than White patients. Inequities in antiplatelet prescribing may contribute…”
Get full text

Evaluation of Potential Racial Disparities in CYP2C19‐Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention by Cavallari, Larisa H., Limdi, Nita A., Beitelshees, Amber L., Lee, James C., Duarte, Julio D., Franchi, Francesco, Tuteja, Sony, Giri, Jay, Empey, Philip E., Kreutz, Rolf P., Skaar, Todd C., Allen, John M., Coons, James C., Gong, Yan, McDonough, Caitrin W., Stevenson, James M., Thomas, Cameron D., Johnson, Julie A., Stouffer, George A., Angiolillo, Dominick J., Lee, Craig R.

“…Black patients suffer worse outcomes after percutaneous coronary intervention (PCI) than White patients. Inequities in antiplatelet prescribing may contribute…”
Get full text

Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US by Wang, Yehua, Cavallari, Larisa H, Brown, Joshua D, Thomas, Cameron D, Winterstein, Almut G

“…A platelet ADP P2Y12 receptor (P2Y12) inhibitor plus aspirin is standard therapy for patients undergoing percutaneous coronary intervention (PCI) for acute…”
Get full text

Evaluation of the protective effects of β‐blockers in the management of acute exacerbations of chronic obstructive pulmonary disease by Thomas, Cameron D., Dupree, Lori H., DeLosSantos, Marci, Ferreira, Jason A.

“…Summary What is known and objective The purpose of this study was to evaluate the association between early β‐blocker continuation and major inpatient events…”
Get full text

Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators by Cavallari, Larisa H., Cicali, Emily, Wiisanen, Kristin, Fillingim, Roger B., Chakraborty, Hrishikesh, Myers, Rachel A., Blake, Kathryn V., Asiyanbola, Bolanle, Baye, Jordan F., Bronson, Wesley H., Cook, Kelsey J., Elwood, Erica N., Gray, Chancellor F., Gong, Yan, Hines, Lindsay, Kannry, Joseph, Kucher, Natalie, Lynch, Sheryl, Nguyen, Khoa A., Obeng, Aniwaa Owusu, Pratt, Victoria M., Prieto, Hernan A., Ramos, Michelle, Sadeghpour, Azita, Singh, Rajbir, Rosenman, Marc, Starostik, Petr, Thomas, Cameron D., Tillman, Emma, Dexter, Paul R., Horowitz, Carol R., Orlando, Lori A., Peterson, Josh F., Skaar, Todd C., Van Driest, Sara L., Volpi, Simona, Voora, Deepak, Parvataneni, Hari K., Johnson, Julie A.

“…Opioid prescribing for postoperative pain management is challenging because of inter‐patient variability in opioid response and concern about opioid addiction…”
Get full text